Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Harvard Business School
Dow

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Linezolid - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for linezolid and what is the scope of freedom to operate?

Linezolid is the generic ingredient in three branded drugs marketed by Hikma, Pharmacia And Upjohn, Aurobindo Pharma Ltd, Fresenius Kabi Usa, Hospira Inc, Hq Spclt Pharma, Mylan Labs Ltd, Nang Kuang Pharm Co, Sagent Pharms Inc, Sandoz Inc, Teva Pharms, Alembic Pharms Ltd, Alkem Labs Ltd, Amneal Pharms, Celltrion, Gate Pharms, Glenmark Pharms, Hetero Labs Ltd V, Mylan, Novel Labs Inc, Teva Pharms Usa, and Zydus Pharms, and is included in twenty-five NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Linezolid has seventy-nine patent family members in thirty-six countries.

There are twenty-two drug master file entries for linezolid. Twenty-six suppliers are listed for this compound.

Drug Prices for linezolid

See drug prices for linezolid

Recent Clinical Trials for linezolid

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
European UnionPhase 3
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)Phase 3
European and Developing Countries Clinical Trials Partnership (EDCTP)Phase 3

See all linezolid clinical trials

Recent Litigation for linezolid

Identify potential future generic entrants

District Court Litigation
Case NameDate
SYMED LABS LIMITED v. ROXANE LABORATORIES, INC.2015-11-25
Pharmacia & Upjohn Company LLC v. Apotex, Inc.2013-03-15

See all linezolid litigation

Pharmacology for linezolid
Medical Subject Heading (MeSH) Categories for linezolid
Synonyms for linezolid
(Linezolid)N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
(S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-5-[(1-hydroxy-ethylamino)-methyl]-oxazolidin-2-one
(S)-N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
(S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
(S)-N-((3-fluoro-4-morpholinophenyl)-2-oxaoxazolidin-5-yl)methyl)acetamide
(S)-N-[ [3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-oxazolidin-5-yl]methyl]-acetamide
(S)-N-[[3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide
(S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide
(S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
111GE017
165800-03-3
800L033
A810662
AB0012049
AB00639994_10
AB00639994_11
AB00639994-06
AB00639994-08
AB00639994-09
AC1L9B3M
Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-
Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)-
Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-
AJ-32488
AK105905
AKOS016340522
AM84567
AN-15409
AX8042607
BCP05586
BCP9000855
BDBM50116067
Benzotriazol-2-yl-acetonitrile
BIDD:GT0404
C-20237
C08146
C16H20FN3O4
CAS-165800-03-3
CC-29960
CCG-101009
CHEBI:63607
CHEMBL126
cid_441401
CJ-07345
CPD000466335
CS-0756
D00947
DB00601
DSSTox_CID_26489
DSSTox_GSID_46489
DSSTox_RID_81660
DTXSID5046489
FT-0080803
FT-0602524
GA2609
HMS2051F08
HMS2089K06
HMS3260C14
HMS3713K10
HSDB 7478
HY-10394
ISQ9I6J12J
J90009
KS-00000BB5
KS-1178
Linezlid
Linezoid
Linezolid (JAN/USAN/INN)
Linezolid (PNU-100766)
Linezolid (Zyvox)
Linezolid [USAN:INN:BAN]
Linezolid [USAN:INN]
Linezolid & VRC3375
Linezolid, >=98% (HPLC)
Linezolid, 98%
Linezolid, Pharmaceutical Secondary Standard; Certified Reference Material
Linezolid, United States Pharmacopeia (USP) Reference Standard
Linezolid|165800-03-3|Zyvoxid
LINEZOLIDE
Linezolidum
LS-173594
M-8338
MFCD00937825
MLS000759444
MLS001424075
MolPort-003-986-503
N-(((5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl)-acetamide
N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
N-((S)-2-oxo-3-(S)-2,3,3a,4-tetrahydro-1H-benzo[b]pyrrolo[1,2-d][1,4]oxazin-7-yl-oxazolidin-5-ylmethyl)-acetamide
N-({(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide
N-[(R)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
N-[(S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
N-[[(5S)-3-(3-fluoranyl-4-morpholin-4-yl-phenyl)-2-oxidanylidene-1,3-oxazolidin-5-yl]methyl]ethanamide
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
N-[[(5S)-3-(3-fluoro-4-morpholino-phenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide
N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide(linezolid)
N-{[(5s)-3-(3-Fluoro-4-Morpholin-4-Ylphenyl)-2-Oxo-1,3-Oxazolidin-5-Yl]methyl}acetamide
N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
NC00259
NCGC00164628-01
NCGC00260781-01
NCGC00263531-03
NCGC00263531-10
NDA 21-130 Zyvox (linezolid tablets)
NDA 21-131 Zyvox for injection (linezolid injection)
NDA 21-132 Zyvox oral suspension (linzolid oral suspension)
PNU 100766
PNU-100766
Q-201308
QCR-88
s1408
SAM001246624
SC-11638
SCHEMBL5027
SMR000466335
SR-01000759376
SR-01000759376-4
SR-01000759376-5
ST2408359
SW197639-3
SYN3021
TL8001272
Tox21_112246
Tox21_500096
TYZROVQLWOKYKF-ZDUSSCGKSA-N
U 100766
U-100,766
U-100766
UNII-ISQ9I6J12J
ZINC2008866
Zivoxid
ZLD
Zyvox
Zyvox (TN)
Zyvox; PNU 100766; U 100766
Zyvoxa
Zyvoxam
Zyvoxid
Paragraph IV (Patent) Challenges for LINEZOLID
Tradename Dosage Ingredient NDA Submissiondate
ZYVOX SOLUTION;INTRAVENOUS linezolid 021131 2009-12-29
ZYVOX SOLUTION;INTRAVENOUS linezolid 021131 2009-09-01
ZYVOX FOR SUSPENSION;ORAL linezolid 021132 2009-08-03
ZYVOX TABLET;ORAL linezolid 021130 2005-12-21

US Patents and Regulatory Information for linezolid

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn ZYVOX linezolid TABLET;ORAL 021130-001 Apr 18, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Alkem Labs Ltd LINEZOLID linezolid TABLET;ORAL 205517-001 Dec 21, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa LINEZOLID linezolid SOLUTION;INTRAVENOUS 204764-001 Mar 15, 2016 AP RX No No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn ZYVOX linezolid TABLET;ORAL 021130-001 Apr 18, 2000 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Hetero Labs Ltd V LINEZOLID linezolid TABLET;ORAL 204239-001 Dec 21, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn ZYVOX linezolid FOR SUSPENSION;ORAL 021132-001 Apr 18, 2000 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Hq Spclt Pharma LINEZOLID linezolid SOLUTION;INTRAVENOUS 207001-001 Jul 7, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for linezolid

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn ZYVOX linezolid FOR SUSPENSION;ORAL 021132-001 Apr 18, 2000   Start Trial   Start Trial
Pharmacia And Upjohn ZYVOX linezolid TABLET;ORAL 021130-002 Apr 18, 2000   Start Trial   Start Trial
Pharmacia And Upjohn ZYVOX linezolid SOLUTION;INTRAVENOUS 021131-001 Apr 18, 2000   Start Trial   Start Trial
Pharmacia And Upjohn ZYVOX linezolid TABLET;ORAL 021130-001 Apr 18, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for linezolid

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0717738 02C0005 France   Start Trial PRODUCT NAME: LINEZOLIDE; NAT. REGISTRATION NO/DATE: NL 26 660 20010831; FIRST REGISTRATION: GB - PL 00 32/0261 20010105
0717738 SPC/GB01/025 United Kingdom   Start Trial PRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105
0717738 12/2002 Austria   Start Trial PRODUCT NAME: LINEZOLID; NAT. REGISTRATION NO/DATE: 1-24227 - 1-24230 20011009; FIRST REGISTRATION: GB PL 00032/0259 - PL 00032/0262 20010105
0717738 PA2004004 Lithuania   Start Trial PRODUCTNAME: LINEZOLIDUM - (S)-N-[[3-FLUOR-4-(4-MORFOLINIL)FENIL]-2-OKSO-5-OKSAZOLIDINIL]METIL]-ACETAMIDAS
0717738 PA2004004,C0717738 Lithuania   Start Trial PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
Johnson and Johnson
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.